Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9884044 | EAGLE PHARMS | Treatment using dantrolene |
Jun, 2022
(1 year, 10 months ago) | |
US8604072 | EAGLE PHARMS | Treatment using dantrolene |
Jul, 2022
(1 year, 8 months ago) | |
US8110225 | EAGLE PHARMS | Treatment using dantrolene |
Dec, 2022
(1 year, 3 months ago) | |
US8685460 | EAGLE PHARMS | Treatment using dantrolene |
Feb, 2023
(1 year, 2 months ago) | |
US7758890 | EAGLE PHARMS | Treatment using dantrolene |
Jun, 2025
(1 year, 2 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE) | Jul 22, 2021 |
Orphan Drug Exclusivity(ODE-69) | Jul 22, 2021 |
Market Authorisation Date: 22 July, 2014
Treatment: For use in the treatment of malignant hyperthermia in conjunction with appropriate supportive measures and for the prevention of malignant hyperthermia in patients at high risk.
Dosage: FOR SUSPENSION;INTRAVENOUS